J Przedlacki1, J Buczyńska-Chyl2, P Koźmiński3, E Niemczyk4,5, E Wojtaszek6, E Gieglis7, P Żebrowski6, A Podgórzak8, J Wściślak8, M Wieliczko6, J Matuszkiewicz-Rowińska6. 1. Department of Nephrology, Dialysis and Internal Diseases, Medical University of Warsaw, Warsaw, Poland. jprzedlacki@wum.edu.pl. 2. Dialysis Unit, Regional Specialist Hospital, Radom, Poland. 3. Fresenius Dialysis Center, Mława, Poland. 4. Department of Internal Diseases, John Paul II Western Hospital, Grodzisk Mazowiecki, Poland. 5. Fresenius Dialysis Center, Płońsk, Poland. 6. Department of Nephrology, Dialysis and Internal Diseases, Medical University of Warsaw, Warsaw, Poland. 7. Fresenius Dialysis Center, Otwock, Poland. 8. Department of Nephrology, Mazovia Regional Hospital, Siedlce, Poland.
Abstract
We assessed the FRAX® method in 718 hemodialyzed patients in estimating increased risk of bone major and hip fractures. Over two prospective years, statistical analysis showed that FRAX® enables a better assessment of bone major fracture risk in these patients than any of its components and other risk factors considered in the analysis. INTRODUCTION: Despite the generally increased risk of bone fractures among patients with end-stage renal disease, no prediction models for identifying individuals at particular risk have been developed to date. The goal of this prospective, multicenter observational study was to assess the usefulness of the FRAX® method in comparison to all its elements considered separately, selected factors associated with renal disease and the history of falls, in estimating increased risk of low-energy major bone and hip fractures in patients undergoing chronic hemodialysis. METHODS: The study included a total of 1068 hemodialysis patients, who were followed for 2 years, and finally, 718 of them were analyzed. The risk analysis included the Polish version of the FRAX® calculator (without bone mineral density), dialysis vintage, mineral metabolism disorders (serum calcium, phosphate, and parathyroid hormone), and the number of falls during the last year before the study. RESULTS: Over 2 years, low-energy 30 major bone fractures were diagnosed and 13 of hip fractures among them. Area under the curve for FRAX® was 0.76 (95% CI 0.69-0.84) for major fractures and 0.70 (95% CI 0.563-0.832) for hip fractures. The AUC for major bone fractures was significantly higher than for all elements of the FRAX® calculator. In logistic regression analysis FRAX® was the strongest independent risk factor of assessment of the major bone fracture risk. CONCLUSIONS: FRAX® enables a better assessment of major bone fracture risk in ESRD patients undergoing hemodialysis than any of its components and other risk factors considered in the analysis.
We assessed the FRAX® method in 718 hemodialyzed patients in estimating increased risk of bone major and hip fractures. Over two prospective years, statistical analysis showed that FRAX® enables a better assessment of bone major fracture risk in these patients than any of its components and other risk factors considered in the analysis. INTRODUCTION: Despite the generally increased risk of bone fractures among patients with end-stage renal disease, no prediction models for identifying individuals at particular risk have been developed to date. The goal of this prospective, multicenter observational study was to assess the usefulness of the FRAX® method in comparison to all its elements considered separately, selected factors associated with renal disease and the history of falls, in estimating increased risk of low-energy major bone and hip fractures in patients undergoing chronic hemodialysis. METHODS: The study included a total of 1068 hemodialysis patients, who were followed for 2 years, and finally, 718 of them were analyzed. The risk analysis included the Polish version of the FRAX® calculator (without bone mineral density), dialysis vintage, mineral metabolism disorders (serum calcium, phosphate, and parathyroid hormone), and the number of falls during the last year before the study. RESULTS: Over 2 years, low-energy 30 major bone fractures were diagnosed and 13 of hip fractures among them. Area under the curve for FRAX® was 0.76 (95% CI 0.69-0.84) for major fractures and 0.70 (95% CI 0.563-0.832) for hip fractures. The AUC for major bone fractures was significantly higher than for all elements of the FRAX® calculator. In logistic regression analysis FRAX® was the strongest independent risk factor of assessment of the major bone fracture risk. CONCLUSIONS: FRAX® enables a better assessment of major bone fracture risk in ESRDpatients undergoing hemodialysis than any of its components and other risk factors considered in the analysis.
Entities:
Keywords:
Bone fracture; Chronic kidney disease; Dialysis; FRAX®; Falls
Authors: Mark D Danese; John Kim; Quan V Doan; Michelle Dylan; Robert Griffiths; Glenn M Chertow Journal: Am J Kidney Dis Date: 2006-01 Impact factor: 8.860
Authors: John A Kanis; Anders Oden; Helena Johansson; Fredrik Borgström; Oskar Ström; Eugene McCloskey Journal: Bone Date: 2009-02-03 Impact factor: 4.398
Authors: C O Stehman-Breen; D J Sherrard; A M Alem; D L Gillen; S R Heckbert; C S Wong; A Ball; N S Weiss Journal: Kidney Int Date: 2000-11 Impact factor: 10.612
Authors: A M Alem; D J Sherrard; D L Gillen; N S Weiss; S A Beresford; S R Heckbert; C Wong; C Stehman-Breen Journal: Kidney Int Date: 2000-07 Impact factor: 10.612
Authors: K S Bezerra de Carvalho; R F V Vasco; M R Custodio; V Jorgetti; R M A Moysés; R M Elias Journal: Osteoporos Int Date: 2019-01-28 Impact factor: 4.507
Authors: P Evenepoel; J Cunningham; S Ferrari; M Haarhaus; M K Javaid; M-H Lafage-Proust; D Prieto-Alhambra; P U Torres; J Cannata-Andia Journal: Osteoporos Int Date: 2021-06-15 Impact factor: 4.507